Serial Number
86843003
Owner
Adaptive Biotechnologies CorporationAttorney
Hoang-chi TruongFiling Date
Dec 8, 2015
DERMASEQ Trademark
Serial Number: 86843003
Trademark Classes
Owner Contact Info
1551 Eastlake Avenue East Suite 200
Seattle, WA 98102
Entity Type: 03
Legal Representation
Trademark Details
Filing Date
December 8, 2015
Registration Date
Not Registered
Goods & Services
Medical services; medical analysis and diagnostic services; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; providing medical diagnostic testing for the detection, diagnosis, and treatment of cutaneous T-cell lymphoma and skin-related cancers; providing medical testing for immune responses to immunotherapy or cancer treatment
Medical and scientific research in the fields of cutaneous T-cell lymphoma and skin-related cancers and diagnosing and treating same; scientific research, development, engineering, testing, and analytical services for diagnosing and treating cutaneous T-cell lymphoma and skin-related cancers; providing diagnostic assays and diagnostic or prognostic testing for diagnosing cutaneous T-cell lymphoma and skin-related cancers; providing analysis, evaluation, and clinical reports of a patient's condition with regard to cutaneous T-cell lymphoma and skin-related cancers; providing diagnostic assays and diagnostic or prognostic testing for cutaneous T-cell lymphoma and skin-related cancers, and the analysis, evaluation, and reports of those test results to help healthcare professionals determine a patient's diagnosis, prognosis or treatment, to assess the effectiveness of patient treatments, and to revise future treatments accordingly; research and development of diagnostic test kits for detecting and diagnosing cutaneous T-cell lymphoma and skin-related cancers; laboratory research and testing services relating to detecting and diagnosing cutaneous T-cell lymphoma and skin-related cancers; computer services, namely, software as a service (SAAS) services featuring software that provides information, test results for detecting and diagnosing cutaneous T-cell lymphoma and skin-related cancers, and the analysis, evaluation, and reporting of those test results to healthcare professionals to determine a patient's clinical diagnosis, prognosis or treatment, to assess the effectiveness of patient treatments, and to revise future treatments accordingly